| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/24/2005 | WO2005110988A1 Pyridone compounds as inhibitors of bacterial type iii protein secretion systems |
| 11/24/2005 | WO2005110987A1 Piperidine derivatives as nk1 and nk3 antagonists |
| 11/24/2005 | WO2005110985A2 Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (sarms) |
| 11/24/2005 | WO2005110980A2 Aryl sulfones and uses related thereto |
| 11/24/2005 | WO2005110974A1 Substituted cyclohexyl-1,4-diamine derivatives |
| 11/24/2005 | WO2005110972A1 Polymorphic forms of nateglinide |
| 11/24/2005 | WO2005110505A2 Hyaluronic acid based copolymers |
| 11/24/2005 | WO2005110498A1 Preservative for medical devices |
| 11/24/2005 | WO2005110490A1 Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
| 11/24/2005 | WO2005110489A2 Nucleic acid aptamers conjugated to high molecular weight steric groups |
| 11/24/2005 | WO2005110484A2 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration |
| 11/24/2005 | WO2005110483A2 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 11/24/2005 | WO2005110482A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic |
| 11/24/2005 | WO2005110480A2 Combination of organic compounds |
| 11/24/2005 | WO2005110478A2 Combination therapy for treating fibrotic disorders |
| 11/24/2005 | WO2005110477A2 Combination therapies for cancer and proliferative angiopathies |
| 11/24/2005 | WO2005110473A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 11/24/2005 | WO2005110464A2 Irx5 inhibition as treatment for hyperproliferative disorders |
| 11/24/2005 | WO2005110462A2 Methods and compositions for treatment of preeclampsia |
| 11/24/2005 | WO2005110455A2 Combination therapy for treating hepatitis virus infection |
| 11/24/2005 | WO2005110451A1 Coffee bean extract, extraction method and composition containing the extract |
| 11/24/2005 | WO2005110448A2 Nutritional composition for increasing creatine uptake in skeletal muscle |
| 11/24/2005 | WO2005110447A1 Oral administration preparation for skin brightness improvement |
| 11/24/2005 | WO2005110442A2 Peritoneal dialysis solution |
| 11/24/2005 | WO2005110440A1 Stabilizers for hydrolyzable organic binders |
| 11/24/2005 | WO2005110439A2 Stabilized hyaluronan preparations and related methods |
| 11/24/2005 | WO2005110438A2 Methods and products related to the intracellular delivery of polysaccharides |
| 11/24/2005 | WO2005110437A2 Implantable biostructure comprising an osteoconductive member and an osteoinductive material |
| 11/24/2005 | WO2005110436A2 Macromolecule-containing sustained release intraocular implants and related methods |
| 11/24/2005 | WO2005110435A1 Prevention of arterial restenosis with active vitamin d compounds |
| 11/24/2005 | WO2005110434A1 Topical treatment and prevention of human papilloma virus (hpv) infection |
| 11/24/2005 | WO2005110433A1 Nonhuman animal having expression of bach2 artificially inhibited, and use thereof |
| 11/24/2005 | WO2005110432A1 Method of potentiating bioloigcal actions of living organism being in contact with aqueous environment and/or enlarging area suitable for biological actions |
| 11/24/2005 | WO2005110431A1 Herbal product containing glucosamine |
| 11/24/2005 | WO2005110430A1 Method of use of carboxylated polysaccharides topically on the eyeball |
| 11/24/2005 | WO2005110429A1 Pharmaceutical compositions for metabolic insufficiences |
| 11/24/2005 | WO2005110428A2 Resistance-repellent retroviral protease inhibitors |
| 11/24/2005 | WO2005110427A1 Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients |
| 11/24/2005 | WO2005110426A1 Vascular damaging agents for administration as an intravenous infusion |
| 11/24/2005 | WO2005110425A1 Polymer-based sustained release device |
| 11/24/2005 | WO2005110424A1 Biodegradable intraocular implants containing prostamides |
| 11/24/2005 | WO2005110423A2 Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias |
| 11/24/2005 | WO2005110422A2 Treatment of diseases associated with altered level of amyloid beta peptides |
| 11/24/2005 | WO2005110421A2 Aerosol formulation for inhalation of beta agonists |
| 11/24/2005 | WO2005110420A1 Controlled-release formulations containing vardenafil |
| 11/24/2005 | WO2005110419A1 Controlled-release formulations containing vardenafil |
| 11/24/2005 | WO2005110418A2 Transdermal administration of phycotoxins |
| 11/24/2005 | WO2005110417A1 Phycotoxins and uses thereof |
| 11/24/2005 | WO2005110416A2 4,5-disubstituted-2-aryl pyrimidines |
| 11/24/2005 | WO2005110415A1 Hiv integrase inhibitors |
| 11/24/2005 | WO2005110414A2 Hiv integrase inhibitors |
| 11/24/2005 | WO2005110413A2 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 11/24/2005 | WO2005110412A1 Neuroprotective properties of dextrorotatory morphinans |
| 11/24/2005 | WO2005110411A1 Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
| 11/24/2005 | WO2005110410A2 Kinase inhibitors as therapeutic agents |
| 11/24/2005 | WO2005110409A2 Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity |
| 11/24/2005 | WO2005110408A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| 11/24/2005 | WO2005110407A2 Nanoparticle dispersion containing lactam compound |
| 11/24/2005 | WO2005110406A2 Phenyl derivatives for the treatment of abnormal cell growth |
| 11/24/2005 | WO2005110405A1 Compositions for affecting weight loss |
| 11/24/2005 | WO2005110404A2 Compositions and methods for enhancing the effectiveness of a chemotherapeutic agent |
| 11/24/2005 | WO2005110403A1 The non-opiate heroin withdrawal medicines |
| 11/24/2005 | WO2005110402A1 Combinations of glycopyrrolate and beta2 adrenoceptor agonists |
| 11/24/2005 | WO2005110401A1 Pharmaceutical nitrones |
| 11/24/2005 | WO2005110400A1 Lipase inhibitor, cholesterol esterase inhibtor, neutral fat absorption inhibitor, cholesterol absorption inhibitor and cholesterol ester absorption inhibitor |
| 11/24/2005 | WO2005110399A2 Zinc-binding groups for metalloprotein inhibitors |
| 11/24/2005 | WO2005110398A2 Pharmaceutical solution formulations containing 17-aag |
| 11/24/2005 | WO2005110397A1 Treatment of myopia |
| 11/24/2005 | WO2005110396A2 Nitrated lipids and methods of making and using thereof |
| 11/24/2005 | WO2005110395A1 System and device for magnetic drug targeting with magnetic drug carrier particles |
| 11/24/2005 | WO2005110394A1 Therapeutic agent for diabetes |
| 11/24/2005 | WO2005110393A1 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease |
| 11/24/2005 | WO2005110392A1 Methods of modulating flt3 activity |
| 11/24/2005 | WO2005110391A2 Compounds for treating human papillomavirus |
| 11/24/2005 | WO2005110390A1 Novel use of peptide compounds for treating dyskinesia |
| 11/24/2005 | WO2005110389A1 Medicinal agent |
| 11/24/2005 | WO2005110388A1 Use of targeted oxidative therapeutic formulation in treatment of cancer |
| 11/24/2005 | WO2005110387A2 Systems and methods for administering a medical regimen |
| 11/24/2005 | WO2005110386A2 Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers |
| 11/24/2005 | WO2005110385A1 Composition for prolonging the residence time of drugs in the gut and use thereof |
| 11/24/2005 | WO2005110384A2 Apiary veterinary composition |
| 11/24/2005 | WO2005110383A1 The use of kauranes compounds in the manufacture of medicament |
| 11/24/2005 | WO2005110381A1 Topical methadone compositions and methods for using the same |
| 11/24/2005 | WO2005110375A1 Nutritional supplement for treatment of ocular diseases |
| 11/24/2005 | WO2005110374A1 Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| 11/24/2005 | WO2005110373A1 Rapidly soluble granulate of bromohexine or bromohexine hydrochloride, method for the production of said granulate and the use thereof |
| 11/24/2005 | WO2005110372A1 Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water |
| 11/24/2005 | WO2005110368A1 Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision |
| 11/24/2005 | WO2005110367A2 Sustained release intraocular implants and methods for preventing retinal dysfunction |
| 11/24/2005 | WO2005110366A1 An estradiol derivative or an estratopone derivative containing sustained release intraocular implant as well as related methods of manufacturing |
| 11/24/2005 | WO2005110365A1 Intravitreal implants in conjunction with photodynamic therapy to improve vision |
| 11/24/2005 | WO2005110364A2 Drug delivery systems and methods for treatment of an eye |
| 11/24/2005 | WO2005110362A1 Biodegradable ocular implants with long-term release characteristics |
| 11/24/2005 | WO2005110359A1 Inhalation powder formulations containing enantiomerically pure beta-agonists |
| 11/24/2005 | WO2005110358A2 Film-shaped estriol-containing medicament for oral administration |
| 11/24/2005 | WO2005110353A1 Personal care compositions and methods for regulating mammalian hair growth and skin condition |
| 11/24/2005 | WO2005110277A2 Carboxylated polysaccharides and method of preparation and use |
| 11/24/2005 | WO2005110275A1 Methods of treating wounds with gonyautoxins |
| 11/24/2005 | WO2005110124A1 Composition and methods for nutritional management of patients with hepatic disease |
| 11/24/2005 | WO2005110121A1 Synergism of gos and polyfructose |